Filing Flows › Entrada Therapeutics (TRDA) › Q2 2026 › vs Q2 2025
Entrada Therapeutics (TRDA) Q2 2026 vs Q2 2025 (year over year)
Entrada Therapeutics's revenue fell $1.1M (-54%) from $1.9M in Q2 2025 to $898K in Q2 2026.
Entrada Therapeutics, Q2 2026: revenue $898K (-54% year over year), net loss $42.8M, operating cash flow −$32.5M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $898K | $1.9M | −$1.1M | -54% |
| Other income, net | $2.2M | $3.9M | −$1.7M | -43% |
| Net loss | $42.8M | $43.1M | −$340K | -0.8% |
| Costs & expenses | $45.9M | $49.0M | −$3.1M | -6% |
| Operating costs | $45.9M | $48.8M | −$2.9M | -6% |
| Income tax | $35K | $178K | −$143K | -80% |
| Research & development | $35.4M | $37.9M | −$2.5M | -7% |
| General & admin | $10.5M | $10.9M | −$430K | -4% |
| Operating cash sources | $42.8M | $43.1M | −$340K | -0.8% |
| Depreciation | $800K | $1.1M | −$300K | -27% |
| Share-based compensation | $5.2M | $5.0M | $102K | +2% |
| Working capital & other | $4.3M | $7.5M | −$3.1M | -42% |
| Cash used in operations | $32.5M | $29.5M | $3.0M | +10% |
| Net loss absorbed | $42.8M | $43.1M | −$340K | -0.8% |
Questions
How much did Entrada Therapeutics's revenue grow year over year in Q2 2026?
Entrada Therapeutics's revenue fell $1.1M (-54%) from $1.9M in Q2 2025 to $898K in Q2 2026.